Jasper Therapeutics Completes Enrollment for Phase 2 IgA Nephropathy Clinical Trial Cohort

Jasper Therapeutics announced it has completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial data by the end of the year and is expanding the study to include a new cohort for patients with focal segmental glomerulosclerosis (FSGS).

Key Details

• Trial Update: Completed enrollment of 18 patients in stage 1 of the IgAN cohort for the Phase 2 basket study of vensobafusp alfa.
• Upcoming Catalyst: The company expects to report initial interim data from the IgAN cohort by year-end 2026.
• Study Expansion: An additional cohort for focal segmental glomerulosclerosis (FSGS) is being initiated, with the first patient expected to be dosed in Q1 2027.